News

July 17, 2019
Sernova Phase I/II US Clinical Trial for Type-1 Diabetes Advances Following Positive Preliminary Safety and Efficacy Data

July 3, 2019
Sernova Corp Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes

June 27, 2019
Sernovas Principal Investigator to Present Interim Data from the Companys Ongoing Phase I/II Cell Pouch Clinical Trial at the 17th World Congress of the International Pancreas and Islet Transplant Association

May 21, 2019
Sernova Corp Announces Appointment of Deborah Brown to its Board of Directors

April 30, 2019
Sernova Announces Collaboration to Advance Therapeutic Cell Pouch Technologies for the Treatment of Hypothyroidism

April 11, 2019
Sernova Announces First Transplantation of Therapeutic Cells in Cell Pouch for the Company Phase I/II U.S. Clinical Study for Diabetes

February 11, 2019
Sernova Corp Announces First Patient Implanted with Sernova Cell Pouch in a Phase I/II US Clinical Trial for the Treatment of Hypoglycemia Unawareness in Subjects with Type 1 Diabetes

January 30, 2019
Sernova Announces the Appointment of Dr. David Lillicrap, M.D. to its Scientific Advisory Board

January 28, 2019
Sernova to Participate on Diabetes Panel and Present at NobleConXV, 15th Annual Investor Conference January 28th – 29th, 2019

January 17, 2019
Sernova Announces Successful Enrollment Approaching 50% of Subjects in its U.S. Phase I/II Cell Pouch Diabetes Clinical Trial

IR Contact


David Burke
Vice President, Investor Relations
917.751.5713
david.burke@sernova.com

Email Alerts Sign-Up

Scroll to Top